Inclusion Criteria:

- Have advanced or metastatic cancer which is refractory to standard therapy or
subjects for whom there is no known effective therapy.

- Have a histologically or cytologically proven diagnosis of a solid tumor known to
express HER2.

- Have a predicted life expectancy of greater than or equal to 12 weeks.

- Have a Karnofsky Performance Status of greater than or equal to 60%

- Have recovered from toxicities of prior chemotherapy, surgery, or radiotherapy.

Exclusion Criteria:

- Be pregnant or lactating. Women of childbearing potential must have a negative serum
pregnancy test result within 7 days of enrollment into the study. Male and female
subjects of childbearing potential (including women who have been amenorrheic for
less than 1 year) must use appropriate birth control during the entire duration of
the study, or the subject must be surgically sterile.

- Have symptomatic brain metastasis

- Have received any other anti-cancer treatment or investigational drug/treatment
within 28 days prior to study Day 1.

- Have a history of another malignancy within the last 5 years.

- Have inadequate organ function.

- Have heart failure defined by an ejection fraction of less than or equal to 50% as
measured by MUGA.

- Have Class II, III or IV symptoms of heart failure as defined by the New York Heart
Association, or uncontrolled arrhythmias, or recent history of myocardial infarction
or angina pectoris.

- Have a medical condition that may interfere with intake and/or absorption of the
study drug (e.g., gastrectomy or resection of major portion of small intestine).

- Have any other serious disease or condition present at screening or at study Day 1
that might affect life expectancy or make it difficult to successfully manage and
follow the subject according to the protocol.